Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Development of the first non-hydroxamate selective HDAC6 degraders
Tim Keuler, Beate König, Nico Bückreiß, et al.
Chemical Communications (2022) Vol. 58, Iss. 79, pp. 11087-11090
Closed Access | Times Cited: 29

Showing 1-25 of 29 citing articles:

Targeted protein degradation: advances in drug discovery and clinical practice
Guangcai Zhong, Xiaoyu Chang, Weilin Xie, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 22
Solid-Phase Synthesis of Cereblon-Recruiting Selective Histone Deacetylase 6 Degraders (HDAC6 PROTACs) with Antileukemic Activity
Laura Sinatra, Jing Yang, Julian Schliehe‐Diecks, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 24, pp. 16860-16878
Open Access | Times Cited: 42
Difluoromethyl-1,3,4-oxadiazoles Are Selective, Mechanism-Based, and Essentially Irreversible Inhibitors of Histone Deacetylase 6
Beate König, P. R. Watson, Nina Reßing, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 19, pp. 13821-13837
Open Access | Times Cited: 24
Chemical Versatility in Catalysis and Inhibition of the Class IIb Histone Deacetylases
D.W. Christianson
Accounts of Chemical Research (2024) Vol. 57, Iss. 8, pp. 1135-1148
Closed Access | Times Cited: 11
Development of the First-in-Class FEM1B-Recruiting Histone Deacetylase Degraders
Felix Feller, Irina Honin, Martina Miranda, et al.
Journal of Medicinal Chemistry (2025)
Closed Access | Times Cited: 1
Degrading the key component of the inflammasome: Development of an NLRP3 PROTAC
Tim Keuler, Dominic Ferber, Jonas Engelhardt, et al.
Chemical Communications (2025)
Closed Access | Times Cited: 1
Selectivity of Hydroxamate- and Difluoromethyloxadiazole-Based Inhibitors of Histone Deacetylase 6 In Vitro and in Cells
J. Ptáček, Ivan Šnajdr, Jiří Schimer, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 5, pp. 4720-4720
Open Access | Times Cited: 17
Perspectives and new aspects of histone deacetylase inhibitors in the therapy of CNS diseases
Bo Han, Mengfei Wang, Jiayi Li, et al.
European Journal of Medicinal Chemistry (2023) Vol. 258, pp. 115613-115613
Closed Access | Times Cited: 16
Significance of Five-Membered Heterocycles in Human Histone Deacetylase Inhibitors
Anton Frühauf, Martin Behringer, Franz‐Josef Meyer‐Almes
Molecules (2023) Vol. 28, Iss. 15, pp. 5686-5686
Open Access | Times Cited: 16
Selective and Bioavailable HDAC6 2-(Difluoromethyl)-1,3,4-oxadiazole Substrate Inhibitors and Modeling of Their Bioactivation Mechanism
Lena Ripa, Jenny Sandmark, Glyn A. Hughes, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 20, pp. 14188-14207
Closed Access | Times Cited: 15
Advances in designing ternary complexes: Integrating in-silico and biochemical methods for PROTAC optimisation in target protein degradation
Shareef Shaik, Prasanna Kumar Reddy Gayam, Manish Chaudhary, et al.
Bioorganic Chemistry (2024) Vol. 153, pp. 107868-107868
Open Access | Times Cited: 5
Pharmacological inhibition of HDAC6 suppresses NLRP3 inflammasome-mediated IL-1β release
Judith Bockstiegel, Silas Wurnig, Jonas Engelhardt, et al.
Biochemical Pharmacology (2023) Vol. 215, pp. 115693-115693
Closed Access | Times Cited: 13
Comprehensive Mechanistic View of the Hydrolysis of Oxadiazole-Based Inhibitors by Histone Deacetylase 6 (HDAC6)
L. Motlova, Ivan Šnajdr, Zsófia Kutil, et al.
ACS Chemical Biology (2023) Vol. 18, Iss. 7, pp. 1594-1610
Open Access | Times Cited: 11
Monoselective Histone Deacetylase 6 PROTAC Degrader Shows In Vivo Tractability
Harsimran Kaur Garcha, Olasunkanmi O. Olaoye, Abootaleb Sedighi, et al.
Journal of Medicinal Chemistry (2025)
Closed Access
Technologies of targeting histone deacetylase in drug discovery: Current progress and emerging prospects
Jinxiao Ru, Yuxi Wang, Zijia Li, et al.
European Journal of Medicinal Chemistry (2023) Vol. 261, pp. 115800-115800
Closed Access | Times Cited: 10
HDAC6 mediates tumorigenesis during mitosis and the development of targeted deactivating agents
Jie Peng, Hongyan Liu, Yujing Liu, et al.
Bioorganic Chemistry (2024) Vol. 153, pp. 107818-107818
Closed Access | Times Cited: 3
Drug Discovery for Histone Deacetylase Inhibition: Past, Present and Future of Zinc-Binding Groups
Gustavo Salgado Pires, Heber Victor Tolomeu, Daniel A. Rodrigues, et al.
Pharmaceuticals (2025) Vol. 18, Iss. 4, pp. 577-577
Open Access
PROTAC chemical probes for histone deacetylase enzymes
Urvashi Patel, Joshua P. Smalley, James T. Hodgkinson
RSC Chemical Biology (2023) Vol. 4, Iss. 9, pp. 623-634
Open Access | Times Cited: 9
Expanding the Structural Diversity at the Phenylene Core of Ligands for the von Hippel–Lindau E3 Ubiquitin Ligase: Development of Highly Potent Hypoxia-Inducible Factor-1α Stabilizers
Lan Phuong Vu, Claudia J. Diehl, Ryan Casement, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 18, pp. 12776-12811
Open Access | Times Cited: 8
Accessing three-branched high-affinity cereblon ligands for molecular glue and protein degrader design
Robert D. Kuchta, Christopher Heim, Alexander Herrmann, et al.
RSC Chemical Biology (2023) Vol. 4, Iss. 3, pp. 229-234
Open Access | Times Cited: 7
2-(Difluoromethyl)-1,3,4-oxadiazoles: The Future of Selective Histone Deacetylase 6 Modulation?
Beate König, Finn K. Hansen
ACS Pharmacology & Translational Science (2024) Vol. 7, Iss. 3, pp. 899-903
Open Access | Times Cited: 2
Tackling Triple Negative Breast Cancer with HDAC inhibitors: 6 is the isoform!
A Guadagni, Simona Barone, Antonella Ilenia Alfano, et al.
European Journal of Medicinal Chemistry (2024) Vol. 279, pp. 116884-116884
Open Access | Times Cited: 2
The Impact of Fluorination on the Design of Histone Deacetylase Inhibitors
Duong Tien Anh, Nguyen‐Hai Nam, Brigitte Kircher, et al.
Molecules (2023) Vol. 28, Iss. 4, pp. 1973-1973
Open Access | Times Cited: 6
Targeted Protein Degradation of Histone Deacetylases by Hydrophobically Tagged Inhibitors
Felix Feller, Finn K. Hansen
ACS Medicinal Chemistry Letters (2023) Vol. 14, Iss. 12, pp. 1863-1868
Closed Access | Times Cited: 6
Targeting reversible post-translational modifications with PROTACs: a focus on enzymes modifying protein lysine and arginine residues
Marta Pichlak, Tomasz Sobierajski, K. M. Błażewska, et al.
Journal of Enzyme Inhibition and Medicinal Chemistry (2023) Vol. 38, Iss. 1
Open Access | Times Cited: 4
Page 1 - Next Page

Scroll to top